VERU
- Veru Inc.
()
Overview
Company Summary
Veru Inc. (VERU) is a biopharmaceutical company that focuses on developing and commercializing innovative medical solutions for men's and women's health. The company operates through two segments: Commercial, which includes the commercialization of prescription medications and consumer health products, and Research and Development (R&D), which encompasses the discovery and development of novel drugs.
In men's health, Veru primarily focuses on developing therapies to address various prostate cancer treatment gaps. They have a flagship product called COUMADIN� (Warfarin) which is an oral anticoagulant used to prevent and treat blood clots. Additionally, they are working on novel drug candidates like Zuclomiphene citrate, which is being developed as a potential nonsteroidal alternative for the treatment of male hypogonadism.
In women's health, the company focuses on developing innovative products to enhance sexual health and well-being. They offer a range of FDA-approved consumer health products, including FC2 Female Condom�, a contraceptive barrier method, and Fiera�, a personal care device designed to enhance sexual arousal and response in women.
Furthermore, Veru's R&D efforts are dedicated to advancing therapies for prostate cancer and female reproductive tract cancers. They have several early-stage pipeline candidates, such as VERU-944, which targets both prostate and breast cancers, and VERU-111, an oral antitubulin agent being developed for metastatic castration and androgen receptor targeting. These investigational drugs are aimed at addressing unmet medical needs and improving patient outcomes.
Overall, Veru Inc. strives to bring innovative medical solutions to market that cater to the specific needs of men and women, with a focus on addressing prostate and breast cancers, male hypogonadism, and sexual health.